280 related articles for article (PubMed ID: 9156266)
21. von Willebrand factor as a marker of endothelial cell activation following BMT.
Collins PW; Gutteridge CN; O'Driscoll A; Blair S; Jones L; Aitchison R; Kelsey SM; Chopra R; Goldstone A; Newland AC
Bone Marrow Transplant; 1992 Dec; 10(6):499-506. PubMed ID: 1490199
[TBL] [Abstract][Full Text] [Related]
22. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
[TBL] [Abstract][Full Text] [Related]
23. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
Terra SG; Spitzer TR; Tsunoda SM
Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
[TBL] [Abstract][Full Text] [Related]
24. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin.
Rio B; Bauduer F; Arrago JP; Zittoun R
Bone Marrow Transplant; 1993 Jun; 11(6):471-2. PubMed ID: 8334428
[TBL] [Abstract][Full Text] [Related]
25. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
26. Parenteral glutamine protects hepatic function during bone marrow transplantation.
Brown SA; Goringe A; Fegan C; Davies SV; Giddings J; Whittaker JA; Burnett AK; Poynton CH
Bone Marrow Transplant; 1998 Aug; 22(3):281-4. PubMed ID: 9720743
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
[TBL] [Abstract][Full Text] [Related]
28. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population.
Sartori MT; Spiezia L; Cesaro S; Messina C; Paris M; Pillon M; Saggiorato G; Pagnan A; Girolami A; Zanesco L; Cella G
Thromb Haemost; 2005 Apr; 93(4):682-9. PubMed ID: 15841312
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
Yoshimi A; Kato K; Maeda N; Matsuyama T; Kojima S
Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
[TBL] [Abstract][Full Text] [Related]
30. [Hypercoagulability in patients with veno-occlusive disease after bone marrow transplantation].
Salat C; Holler E; Reinhardt B; Kolb HJ; Pihusch R; Neumeister P; Hiller E
Med Klin (Munich); 1994 May; 89(5):245-7. PubMed ID: 8052177
[TBL] [Abstract][Full Text] [Related]
31. [Tendency to thrombosis following bone marrow transplantation?].
Tsakiris DA; Huser B; Gratwohl A; Marbet GA
Schweiz Med Wochenschr; 1991 Mar; 121(10):341-3. PubMed ID: 1902984
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
[TBL] [Abstract][Full Text] [Related]
33. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
[TBL] [Abstract][Full Text] [Related]
34. Humoral coagulation and early complications after allogeneic bone marrow transplantation.
Nürnberger W; Kruck H; Mauz-Körholz C; Burdach S; Göbel U
Klin Padiatr; 1997; 209(4):209-15. PubMed ID: 9293452
[TBL] [Abstract][Full Text] [Related]
35. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate.
Patton DF; Harper JL; Wooldridge TN; Gordon BG; Coccia P; Haire WD
Bone Marrow Transplant; 1996 Mar; 17(3):443-7. PubMed ID: 8704704
[TBL] [Abstract][Full Text] [Related]
36. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
[TBL] [Abstract][Full Text] [Related]
37. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
[TBL] [Abstract][Full Text] [Related]
38. Endothelium and bone marrow transplantation.
Catani L; Gugliotta L; Vianelli N; Nocentini F; Baravelli S; Bandini G; Cirio TM; Tura S
Bone Marrow Transplant; 1996 Feb; 17(2):277-80. PubMed ID: 8640179
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
[TBL] [Abstract][Full Text] [Related]
40. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation.
Azoulay D; Castaing D; Lemoine A; Hargreaves GM; Bismuth H
Bone Marrow Transplant; 2000 May; 25(9):987-92. PubMed ID: 10800068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
